Alnylam's genetic disease drug clears key study, shares soar

(Reuters) - Alnylam Pharmaceuticals Inc said its drug to treat patients suffering from a rare genetic disease met the main goal in a late-stage study, moving the company closer to filing a marketing application for the drug in late 2017.